Hope for stargardt patients: new drug aims to slow blindness
Disease control
Recruiting now
This Phase 3 trial tests an oral drug called gildeuretinol acetate (ALK 001) in 230 people aged 8 to 45 with Stargardt disease, a genetic condition that causes progressive vision loss. Participants take the drug or a placebo daily for 24 months. The goal is to see if the drug can…
Phase: PHASE3 • Sponsor: Alkeus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC